Apollomics (NASDAQ:APLM) Upgraded at Wall Street Zen

Key Points

• Wall Street Zen upgraded Apollomics to “Hold,” while Weiss Ratings also adjusted its assessment but still rated the stock “Sell.” MarketBeat reports an average analyst rating of “Sell.”
• Apollomics shares opened at $24.33, compared with a one-year range of $3.66 to $42.12; the 50-day and 200-day moving averages were $19.03 and $17.47, respectively.
• Company insiders made significant purchases, acquiring 583,334 shares worth $8.25 million over the past 90 days. Separately, Kestra Advisory Services established a new 4,380-share position, while institutions collectively owned 19.13% of Apollomics.

Apollomics (NASDAQ:APLM - Get Free Report) was upgraded by research analysts at Wall Street Zen to a "hold" rating in a research note issued on Saturday.

Separately, Weiss Ratings raised shares of Apollomics from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Monday. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has an average rating of "Sell".

Apollomics Price Performance

APLM stock opened at $24.33 on Friday. Apollomics has a one year low of $3.66 and a one year high of $42.12. The firm has a 50-day simple moving average of $19.03 and a two-hundred day simple moving average of $17.47.

Insider Buying and Selling at Apollomics

In other Apollomics news, COO Yi-Kuei Chen purchased 20,000 shares of the firm's stock in a transaction on Friday, August 14th. The stock was bought at an average cost of $15.00 per share, for a total transaction of $300,000.00. Following the completion of the purchase, the chief operating officer owned 121,248 shares in the company, valued at $1,818,720. This represents a 19.75% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Peter Kuan-How Lin purchased 26,667 shares of the stock in a transaction on Friday, August 14th. The stock was acquired at an average cost of $15.00 per share, with a total value of $400,005.00. Following the acquisition, the chief financial officer owned 48,979 shares of the company's stock, valued at approximately $734,685. This represents a 119.52% increase in their position. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders acquired 583,334 shares of company stock worth $8,250,510.

Institutional Trading of Apollomics

An institutional investor recently bought a new stake in Apollomics stock. Kestra Advisory Services LLC purchased a new stake in shares of Apollomics Inc. (NASDAQ:APLM - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 4,380 shares of the company's stock, valued at approximately $82,000. Kestra Advisory Services LLC owned approximately 0.40% of Apollomics at the end of the most recent quarter. Hedge funds and other institutional investors own 19.13% of the company's stock.

About Apollomics

Apollomics, Inc, a clinical-stage biopharmaceutical company based in Palo Alto, California, focuses on the development of innovative targeted therapies and immuno-oncology agents for the treatment of cancer. The company's research and development efforts center on small molecule inhibitors and monoclonal antibodies designed to address key pathways involved in tumor growth and immune evasion. Its lead asset, dalpiciclib (formerly SHP654), is a selective oral CDK4/6 inhibitor in Phase III trials for metastatic breast cancer, and Apollomics holds a number of additional early-stage programs targeting solid tumors and hematologic malignancies.

Founded in 2015, Apollomics has established research and clinical collaboration networks across North America, China and Europe.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source